Figure 4B shows the changes in caspases-3 activity in the CLL cells treated with the miRNA-15a, fludarabine and their combination for 24 h that indicate the caspase-3 activity was increased by 1.77, 4.36, and 7.18 times, respectively, compared with blank control cells (p<0.05). As indicated in Figure 4B, miRNA-15a alone and in combination with fludarabine activated caspase-3 activity in a time dependent manner. This evidence concerns the gene CASP3 and B-cell chronic lymphocytic leukemia.